Promising Preliminary Results in Optic Nerve Recovery Study of NurExone’s first product ExoPTEN for Glaucoma

NurExone Biologic Inc. is pleased to announce the preliminary results from a small-scale controlled study exploring the use of its flagship nanodrug, ExoPTEN , for optic nerve recovery in a rat model at Sheba Medical Center .

The study was initiated by Professor Michael Belkin , following the success of ExoptEN in nerve regeneration in the spinal cord indication in preclinical models.

The prevalence of glaucoma in the Western world is generally estimated to be 2-3% in people aged 40 and older.

The Company’s first product, ExoPTEN for acute spinal cord injury, was proven to recover motor function in 75% of laboratory rats when administered intranasally.

NurExone platform technology is expected to offer novel solutions to drug companies interested in noninvasive targeted drug delivery for other indications.

The Company cannot assure readers that actual results will be consistent with these forward-looking statements.

The Company assumes no obligation to update or revise them to reflect new events or circumstances.

Neither TSXV nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.